Eiger BioPharmaceuticals, Inc. (EIGR)
(Delayed Data from NSDQ)
$10.50 USD
-0.22 (-2.05%)
Updated May 3, 2019 04:00 PM ET
After-Market: $10.53 (%) 5:22 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Eiger BioPharmaceuticals, Inc. [EIGR]
Reports for Purchase
Showing records 101 - 112 ( 112 total )
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 31
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 24
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences - Upcoming Events for the Week of Oct 17
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - Progress Continues Forward with HDV and HBV Therapies - AASLD Abstract Takeaways
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Progress Continues Forward with HDV and HBV Therapies - AASLD Abstract Takeaways
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Thinking About Lonafarnib Data Ahead of AASLD Abstract Release; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HDV Data this Year Should Help Position Lonafarnib - Eiger Reports 2Q16; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of July 18
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
The Week Ahead in Life Sciences: Upcoming Events for the Week of June 27
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Subcutaneous Exendin (9-39) Prevents Hypoglycemia, Supporting the Role of GLP-1 Antagonism in BSIHH; Reiterate OUTPERFORM
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H
Company: Eiger BioPharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Initiating Coverage with an OUTPERFORM Rating and $36 Price Target; Rare Disease Focus with HDV up First
Provider: WEDBUSH SECURITIES INC.
Analyst: BEHANNA H